{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.05","upperLimit":"0.57","value":"0.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The biochemical response rate will be estimated by the number of responders(patients that achieved partial or complete response) divided by the number of evaluable patients who have measurable disease by serum M-protein, urine M-protein, or serum FLC assay at baseline. Exact binomial confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dexamethasone: Given PO Ixazomib Citrate: Given PO Laboratory Biomarker Analysis: Correlative studies Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib Citrate, Pomalidomide, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"All patients evaluated for biochemical response","reportingStatus":"POSTED","timeFrame":"4 years","title":"Biochemical Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}